Scenarios that move RGEN
Repligen Corporation - Common Stock
Scenarios that move RGEN: 14 analyses, 12 positive, 2 negative.
- · Ascendis Pharma receives positive CHMP opinion for TransCon CNP — ▲ · impact +20 · confidence low · horizon quarters
- · FDA expands ImmunityBio's Anktiva label for bladder cancer — ▲ · impact +8 · confidence low · horizon quarters
- · Roche reports positive Phase III eye drug data, FDA accepts BLA — ▲ · impact +20 · confidence medium · horizon quarters
- · Viking Therapeutics advances oral obesity drug to Phase III — ▲ · impact +9 · confidence low · horizon quarters
- · SRX Global SPV agrees to acquire CERo Therapeutics — ▲ · impact +6 · confidence low · horizon quarters
- · Vaxcyte prices concurrent stock, warrant and convertible note offerings — ▲ · impact +14 · confidence low · horizon quarters
- · Spyre Therapeutics prices $350 million public stock offering — ▲ · impact +5 · confidence low · horizon quarters
- · Novartis acquires Abogen in $7.8B RNA therapeutics deal — ▲ · impact +10 · confidence low · horizon quarters
- · Genmab and AbbVie report positive epcoritamab lymphoma trial results — ▲ · impact +12 · confidence low · horizon quarters
- · Mirum's Brelovitug meets goal in Phase III AZURE-1 study — ▲ · impact +12 · confidence low · horizon quarters
- · Pharma stock soars 150% after injectables deal with Novo — ▲ · impact +28 · confidence low · horizon quarters
- · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▼ · impact -20 · confidence low · horizon quarters
- · Viking Therapeutics stock skyrockets in Tuesday trading — ▲ · impact +30 · confidence low · horizon quarters
- · Sion cuts workforce nearly half after CF study failure — ▼ · impact -7 · confidence low · horizon quarters